These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 7940801)

  • 1. Clinical algorithms for cyclosporine management based on pathophysiologic constructs of nephrotoxicity.
    Bennett WM
    Transplant Proc; 1994 Oct; 26(5):2583-4. PubMed ID: 7940801
    [No Abstract]   [Full Text] [Related]  

  • 2. FK 506 in a 14-year-old renal allograft recipient with cyclosporine-related liver nephrotoxicity: 1-year follow-up.
    Offner G; Burdelski M; Hoyer PF; Winkler M; Brodehl J
    Transplant Proc; 1991 Dec; 23(6):3082-4. PubMed ID: 1721366
    [No Abstract]   [Full Text] [Related]  

  • 3. Studies of cyclosporine-associated arteriolopathy in renal transplantation: does the long-term outcome of renal allografts depend on chronic cyclosporine nephrotoxicity?
    Takeda A; Morozumi K; Yoshida A; Uchida K; Tominaga Y; Fujinami T; Yokoyama I; Takagi H
    Transplant Proc; 1994 Apr; 26(2):925-8. PubMed ID: 8171705
    [No Abstract]   [Full Text] [Related]  

  • 4. Cyclosporine therapy in pancreas transplantation.
    Davidson I; Lu C; Melone D; Risser R
    Transplant Proc; 1996 Aug; 28(4):2134-5. PubMed ID: 8769179
    [No Abstract]   [Full Text] [Related]  

  • 5. Cyclosporine increases endothelin-1 plasma levels in renal transplant recipients.
    Cauduro RL; Costa C; Lhulier F; Garcia RG; Cabral RD; Gonçalves LE; Manfro RC
    Transplant Proc; 2004 May; 36(4):880-1. PubMed ID: 15194301
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Balancing cyclosporine A nephrotoxicity and rejection late after adult liver transplantation.
    Paul A; Levy GA; Greig PD
    Transplant Proc; 1993 Aug; 25(4):2664-5. PubMed ID: 8356714
    [No Abstract]   [Full Text] [Related]  

  • 7. Long-term results of conversion from existing to microemulsion formulation of cyclosporine.
    Neumayer HH; Färber L; Budde K; Kohnen R; Maibücher A; Schuster A; Vollmar J; Waiser J; Luft FC
    Transplant Proc; 1996 Aug; 28(4):2207-13. PubMed ID: 8769202
    [No Abstract]   [Full Text] [Related]  

  • 8. Studies on morphological outcome of cyclosporine-associated arteriolopathy after discontinuation of cyclosporine in patients with renal allografts.
    Morozumi K; Thiel G; Gudat F; Mihatsch MJ
    Transplant Proc; 1993 Feb; 25(1 Pt 1):537-9. PubMed ID: 8438404
    [No Abstract]   [Full Text] [Related]  

  • 9. Conversion from cyclosporine to tacrolimus in kidney, kidney/pancreas, and pancreas alone transplant recipients: the Memphis experience.
    Alloway RR; Russell WC; Gaber LW; Amiri MH; Vera SR; Gaber AO
    Transplant Proc; 1996 Apr; 28(2):995-7. PubMed ID: 8623494
    [No Abstract]   [Full Text] [Related]  

  • 10. Effect of liver disease in kidney transplant recipients on cyclosporine dose and metabolite levels.
    Alfurayh O; Sobh M; Minhas M; Almeshari K; Alshaibani K; Qunibi W; Aesha H; Taher S
    Transplant Proc; 1994 Oct; 26(5):2655. PubMed ID: 7940830
    [No Abstract]   [Full Text] [Related]  

  • 11. Safety and tolerability of Sandimmun Neoral vs Sandimmun in de novo renal transplant patients after 24 months' treatment. German Neoral Study Group.
    Buchholz B; Korn A
    Transplant Proc; 1996 Aug; 28(4):2187-8. PubMed ID: 8769195
    [No Abstract]   [Full Text] [Related]  

  • 12. The Neoral formulation: improved correlation between cyclosporine trough levels and exposure in stable renal transplant recipients.
    Kahan BD; Dunn J; Fitts C; Van Buren D; Wombolt D; Pollak R; Carson R; Alexander JW; Chang C; Choc M
    Transplant Proc; 1994 Oct; 26(5):2940-3. PubMed ID: 7940928
    [No Abstract]   [Full Text] [Related]  

  • 13. Conversion from cyclosporine to tacrolimus in hepatic and renal transplantation.
    Yussim A; Shaharabani E; Mor E; Lustig S; Bar-Nathan N; Shmueli D; Sobolev V; Dorfman B; Or H; Shapira Z
    Transplant Proc; 1996 Dec; 28(6):3178-9. PubMed ID: 8962233
    [No Abstract]   [Full Text] [Related]  

  • 14. Evaluation of infections in renal transplant recipients treated with cyclosporine.
    Carmellini M; Romagnoli J; Pietrabissa A; Di Stefano R; Oleggini M; Rindi P; Rizzo G; Mosca F
    Transplant Proc; 1994 Oct; 26(5):2658-9. PubMed ID: 7940832
    [No Abstract]   [Full Text] [Related]  

  • 15. Controlled trials with cyclosporine in kidney transplantation.
    Ponticelli C; Tarantino A; Montagnino G
    Transplant Proc; 1994 Oct; 26(5):2490-2. PubMed ID: 7940764
    [No Abstract]   [Full Text] [Related]  

  • 16. [Cyclosporin in transplantation management--especially after kidney transplantation].
    Quellhorst E
    Internist (Berl); 1996 Jan; 37(1):88-90. PubMed ID: 8837834
    [No Abstract]   [Full Text] [Related]  

  • 17. Cyclosporine A toxicity is associated with reduced endothelin immunoreactivity in renal endothelium.
    Watschinger B; Ulrich W; Vychytil A; Traindl O; Seidl S; Kainz H; Klauser R; Wamser P; Kovarik J
    Transplant Proc; 1992 Dec; 24(6):2618-9. PubMed ID: 1465886
    [No Abstract]   [Full Text] [Related]  

  • 18. Improvement in renal function by felodipine during cyclosporine treatment in acute and short-term studies.
    Pedersen EB; Madsen JK; Sørensen SS; Zachariae H
    Kidney Int Suppl; 1996 Jun; 55():S94-6. PubMed ID: 8743522
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of pravastatin on renal transplant recipients treated with cyclosporine--4-year follow-up.
    Yoshimura N; Ohmori Y; Tsuji T; Oka T
    Transplant Proc; 1994 Oct; 26(5):2632-3. PubMed ID: 7940820
    [No Abstract]   [Full Text] [Related]  

  • 20. Renovascular elements of the cyclosporine injury.
    Curtis JJ
    Transplant Proc; 1996 Aug; 28(4):2094-6. PubMed ID: 8769164
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.